News

The filing is based on a global Phase III clinical development program, including nine multicenter, randomized clinical studies, which evaluated the safety and efficacy of canagliflozin across the

The PK substudy will confirm the low levels of systemic exposure previously observed in preclinical studies of the product. The company will collect the blood samples earlier to

With the investment, the company expects to make sure that the supply of substances from the well-stocked research pipeline is available for clinical studies in adequate amounts. Boehringer

In relation to the establishment, Ariana has appointed James Shanahan as VP of business development. James was previously a co-founder and is current board member of SynDevRx. Ariana

The new biosensor is pre-immobilized with novel nickel-charged tri-nitrilotriacetic (Tri-NTA) groups enabling direct method for quantitation and kinetic analysis of polyhistidine-tagged (HIS-tagged) biomolecules. ForteBio division marketing vice president

The randomized, double-blind trial compares TAS-102 with best supportive care (BSC) to investigate the efficacy and safety of TAS-102 when administered to patients who are both unresectable and

The company plans to distribute the product, in 60-count bottles, through multiple online sales channels, independent retailers, and health professionals. Each capsule of For Her Senses contains a

The transaction is subject to approval by Welichem shareholders. Under the agreement, Welichem will receive an initial payment of C$35m and is eligible to receive additional milestone payments

Cabozantinib is a potent targeted therapy that inhibits MET, VEGFR2 and RET. As a part of the NDA filing, which is based on data from a Phase III